Claims for Patent: 10,675,258

Summary for Patent: 10,675,258

Title:	Method of using gamma-hydroxybutyrate compositions for the treatment of disorders
Abstract:	Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.
Inventor(s):	Allphin; Clark P. (Los Altos, CA), DesJardin; Michael (Aptos, CA)
Assignee:	Jazz Pharmaceuticals Ireland Limited (Dublin, IE)
Application Number:	16/230,460
Patent Claims:	1. A method of treating cataplexy or daytime sleepiness in a patient who has been diagnosed with narcolepsy comprising administering orally a pharmaceutical composition of gamma-hydroxybutyrate (GHB) comprising a mixture of salts of GHB, wherein the mixture comprises three or four salts of GHB selected from the group consisting of a sodium salt of GHB (Na.cndot.GHB), a potassium salt of GHB (K.cndot.GHB), a magnesium salt of GHB (Mg.cndot.(GHB).sub.2), and a calcium salt GHB (Ca.cndot.(GHB).sub.2). 2. The method of claim 1, wherein the mixture comprises Na.cndot.GHB, K.cndot.GHB, Mg.cndot.(GHB).sub.2, and Ca.cndot.(GHB).sub.2. 3. The method of claim 2, wherein the Na.cndot.GHB salt is present in a wt/wt % of about 5% to about 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 25%, about 25% to about 30%, about 30% to about 35%, or about 35% to about 40%. 4. The method of claim 2, wherein the K.cndot.GHB salt is present in a wt/wt % of about 10% to about 15%, about 15% to about 20%, about 20% to about 25%, about 25% to about 30%, about 30% to about 35%, or about 35% to about 40%. 5. The method of claim 2, wherein the Mg.cndot.(GHB).sub.2 salt is present in a wt/wt % of about 5% to about 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 25%, or about 25% to about 30%. 6. The method of claim 2, wherein the Ca.cndot.(GHB).sub.2 salt is present in a wt/wt % of about 20% to about 25%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, or about 75% to about 80%. 7. The method of claim 2, wherein the Na.cndot.GHB salt is present in a wt/wt % of about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, or about 40%. 8. The method of claim 2, wherein the K.cndot.GHB salt is present in a wt/wt % of about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, or about 40%. 9. The method of claim 2, wherein the Mg.cndot.(GHB).sub.2 salt is present in a wt/wt % of about 5%, about 10%, about 15%, about 20%, about 25%, or about 30%. 10. The method of claim 2, wherein the Ca.cndot.(GHB).sub.2 salt is present in a wt/wt % of about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, or about 80%. 11. The method of claim 2, wherein the Na.cndot.GHB salt is present in a wt/wt % of about 5% to about 40%, the K.cndot.GHB salt is present in a wt/wt % of about 10% to about 40%, the Mg.cndot.(GHB).sub.2 salt is present in a wt/wt % of about 5% to about 30%, and the Ca.cndot.(GHB).sub.2 salt is present in a wt/wt % of about 20% to about 80%. 12. The method of claim 2, wherein the Na.cndot.GHB, K.cndot.GHB, Mg.cndot.(GHB).sub.2, and Ca.cndot.(GHB).sub.2 salts are present in a wt/wt % ratio of about 8%:32%:20%:40%, respectively. 13. The method of claim 2, wherein the Na.cndot.GHB, K.cndot.GHB, Mg.cndot.(GHB).sub.2, and Ca.cndot.(GHB).sub.2 salts are present in a wt/wt % ratio of about 29%:31%:13%:27%, respectively. 14. The method of claim 2, wherein the Na.cndot.GHB, K.cndot.GHB, Mg.cndot.(GHB).sub.2, and Ca.cndot.(GHB).sub.2 salts are present in a wt/wt % ratio of about 8%:23%:21%:48%, respectively. 15. The method of claim 1, wherein the pharmaceutical composition of GHB comprises an aqueous solution of about 250 mg/mL to about 750 mg/mL of the mixture of salts of GHB, wherein the composition has a pH of about 7.0 to about 9.0, wherein the composition is chemically stable and resistant to microbial growth, and wherein the composition is free of preservatives. 16. The method of claim 15, wherein the composition has a pH of about 7.3 to about 8.5. 17. The method of claim 15, wherein the total concentration of the GHB is between 300 mg/ml to 750 mg/ml. 18. The method of claim 15, wherein the total concentration of the GHB is between 400 mg/ml to 600 mg/ml. 19. The method of claim 1, wherein the total concentration of the mixture of salts of GHB in the solution is about 500 mg/mL. 20. The method of claim 1, wherein the pharmaceutical composition of GHB is formulated as a liquid formulation. 21. The method of claim 1, wherein the pharmaceutical composition of GHB is formulated as a solid formulation. 22. The method of claim 1, wherein the mixture of salts of GHB provides a mean GastroIntestinal transit rate of about 35%. 23. The method of claim 22, wherein the mean GastroIntestinal transit rate is measured as compared to a non-absorbable marker reference. 24. A method of treating cataplexy or daytime sleepiness in a patient who has been diagnosed with narcolepsy comprising administering orally a pharmaceutical composition of gamma-hydroxybutyrate (GHB) comprising a mixture of four salts of GHB, wherein the mixture comprises a sodium salt of GHB (Na.cndot.GHB), a potassium salt of GHB (K.cndot.GHB), a magnesium salt of GHB (Mg.cndot.(GHB).sub.2), and a calcium salt GHB (Ca.cndot.(GHB).sub.2), and wherein the Na.cndot.GHB, K.cndot.GHB, Mg.cndot.(GHB).sub.2, and Ca.cndot.(GHB).sub.2 salts are present in a % molar equivalents ratio of about 8%:23%:21%:48%, respectively. 25. The method of claim 24, wherein the pharmaceutical composition of GHB comprises an aqueous solution of about 250 mg/mL to about 750 mg/mL of the mixture of salts of GHB, wherein the composition has a pH of about 7.0 to about 9.0, wherein the composition is chemically stable and resistant to microbial growth, and wherein the composition is free of preservatives. 26. The method of claim 25, wherein the composition has a pH of about 7.3 to about 8.5. 27. The method of claim 25, wherein the total concentration of the GHB is between 300 mg/ml to 750 mg/ml. 28. The method of claim 25, wherein the total concentration of the GHB is between 400 mg/ml to 600 mg/ml. 29. The method of claim 25, wherein the total concentration of the mixture of salts of GHB in the solution is about 500 mg/mL. 30. The method of claim 24, wherein the pharmaceutical composition of GHB is formulated as a liquid formulation. 31. The method of claim 24, wherein the pharmaceutical composition of GHB is formulated as a solid formulation. 32. The method of claim 24, wherein the mixture of salts of GHB provides a mean GastroIntestinal transit rate of about 35%. 33. The method of claim 32, wherein the mean GastroIntestinal transit rate is measured as compared to a non-absorbable marker reference.